Compile Data Set for Download or QSAR
Report error Found 74 Enz. Inhib. hit(s) with all data for entry = 1314
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316508(2-({(3R,6R)-6-methyl-1-[(3- pyrimidin-2-ylthiophen...)
Affinity DataIC50: 5.30nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316512(Methyl 4-methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,...)
Affinity DataIC50: 11.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316475(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50: 13.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316484(2-{[(3R,6R)-6-methyl-1-{[3-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50: 14.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316490(2-{[(3R,6R)-1-{[5-bromo-2-(2H-1,2,3- triazol-2-yl)...)
Affinity DataIC50: 14.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316486(2-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 15.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316494(2-{[(3R,6R)-1-(biphenyl-2-ylcarbonyl)-6- methylpip...)
Affinity DataIC50: 16.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316496(2-({(3R,6R)-1-[(2- cyclopropylphenyl)carbonyl]-6- ...)
Affinity DataIC50: 18.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316510(2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50: 18.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316507(2-({(3R,6R)-6-methyl-1-[(2- pyrimidin-2- ylphenyl)...)
Affinity DataIC50: 18.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316506(2-({(3R,6R)-6-Methyl-1-[(2-pyrimidin-2-ylthiophen-...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316477(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50: 20nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316485(2-{[(3R,6R)-1-{[3-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 20.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316469(Methyl 4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2...)
Affinity DataIC50: 22.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316472(methyl 4-iodo-2-{[(3R,6R)-6-methyl- 1-{[2-(2H-1,2,...)
Affinity DataIC50: 23.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316471(US9617246, 48 | methyl 2-{[(3R,6R)-6-methyl-1- {[2...)
Affinity DataIC50: 23.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316476(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50: 24.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316487(2-{[(3R,6R)-1-{[4-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 26.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316469(Methyl 4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2...)
Affinity DataIC50: 27.8nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316499(2-{[(3R,6R)-6-methyl-1-{[2-(1- methylethoxy)phenyl...)
Affinity DataIC50: 29.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316497(2-{[(3R,6R)-6-methyl-1-{[2-(1-methyl- 1H-pyrazol-4...)
Affinity DataIC50: 30.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316504(2-{[(3R,6R)-6-methyl-1-{[2-(tetrahydro- 2H-pyran-2...)
Affinity DataIC50: 36.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316471(US9617246, 48 | methyl 2-{[(3R,6R)-6-methyl-1- {[2...)
Affinity DataIC50: 48.1nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316488(2-{[(3R,6R)-6-methyl-1-{[4-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50: 49nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316483(2-{[(3R,6R)-1-{[2-methoxy-6-(2H-1,2,3- triazol-2-y...)
Affinity DataIC50: 51.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316482(2-{[(3R,6R)-1-{[2-fluoro-6-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 51.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316472(methyl 4-iodo-2-{[(3R,6R)-6-methyl- 1-{[2-(2H-1,2,...)
Affinity DataIC50: 54.4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316495(2-({(3R,6R)-6-methyl-1-[(2- phenoxyphenyl)carbonyl...)
Affinity DataIC50: 62.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316498(2-({(3R,6R)-6-methyl-1-[(2- phenylpyridin-3-yl)car...)
Affinity DataIC50: 71.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316512(Methyl 4-methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,...)
Affinity DataIC50: 73.2nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316500(2-{[(3R,6R)-6-methyl-1-{[2- (methylsulfanyl)phenyl...)
Affinity DataIC50: 75.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316470(2-methyl-6-{[(3R,6R)-6-methyl- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 82.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316505(2-({(3R,6R)-6-methyl-1-[(2-pyrrolidin-1- ylphenyl)...)
Affinity DataIC50: 103nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316480(2-{[(3R,6R)-1-{[6-Methoxy-2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 149nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316473(2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50: 179nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316491(2-{[(3R,6R)-1-{[5-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 214nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316489(2-{[(3R,6R)-1-{[4-methoxy-2-(2H-1,2,3- triazol-2-y...)
Affinity DataIC50: 224nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316494(2-{[(3R,6R)-1-(biphenyl-2-ylcarbonyl)-6- methylpip...)
Affinity DataIC50: 279nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316479(methyl 2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triaz...)
Affinity DataIC50: 297nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316474(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50: 322nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316477(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50: 440nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316490(2-{[(3R,6R)-1-{[5-bromo-2-(2H-1,2,3- triazol-2-yl)...)
Affinity DataIC50: 489nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316474(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50: 596nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316471(US9617246, 48 | methyl 2-{[(3R,6R)-6-methyl-1- {[2...)
Affinity DataIC50: 626nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316476(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50: 634nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316484(2-{[(3R,6R)-6-methyl-1-{[3-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50: 803nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316509(2-({(3R,6R)-1-[(6-methoxy-2- pyrimidin-2-ylpyridin...)
Affinity DataIC50: 864nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316486(2-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 1.03E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316475(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50: 1.41E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316488(2-{[(3R,6R)-6-methyl-1-{[4-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50: 1.50E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/10/2019
Entry Details
US Patent

Displayed 1 to 50 (of 74 total ) | Next | Last >>
Jump to: